Immunotherapy Combo Improves Bladder Cancer Event-Free Survival Tara Haelle

https://www.medscape.com/viewarticle/immunotherapy-combo-improves-bladder-cancer-event-free-2026a100148s?ecd=WNL_trdalrt_pos1_ous_261027_etid8837163&uac=148436CN&impID=8837163 Patients with muscle-invasive bladder cancer who received neoadjuvant and adjuvant durvalumab and neoadjuvant enfortumab vedotin with radical cystectomy, with or without peri- and postoperative tremelimumab, had significantly better event-free survival than those who underwent surgery alone.